Novogene Corporation, a Chinese genomics and bioinformatics firm backed by CMB International Capital Management and the State Development & Investment Corporation (SDIC), has jointly established a whole genome sequencing center in Singapore by partnering with two institutions in the city-state.
The two partners are AITbiotech Pte Ltd, a Singapore biotechnology company, and the Genome Institute of Singapore.
The joint venture, named NovogeneAIT Genomics Singapore, will provide whole genome sequencing and bioinformatics analysis of human, plant and animal samples for biomedical and agricultural researchers.
"The center is the first major project for NovogeneAIT and is an important milestone for our company. We look forward to providing high-quality sequencing services in Singapore and to advancing important research initiatives that can benefit humanity," said Dr. Ruiqiang Li, CEO of Novogene.
The center will devote a major portion of its sequencing capability to support public research projects and empower super scale sequencing initiatives in Singapore and the region.
In addition, NovogeneAIT will collaborate with Genome Institute of Singapore to develop new applications of next-generation sequencing, such as WGS solutions for cancer diagnosis and stratified cancer treatment.
"Such public-private partnerships will prove to be highly beneficial as it leverages the strengths of both parties to advance genomic science and medicine in Singapore," said Prof. Ng Huck Hui, executive director of Genome Institute of Singapore.
Last week, CMB International, a unit of State Development & Investment Corporation (SDIC) in China, and Sigma Square Capital invested RMB515 million (US$75 million) in a series B funding round in Beijing-based Novogene.